Introduction
In February 2026, Korea’s Ministry of Food and Drug Safety (MFDS) approved 39 new INDs, sustaining the strong start seen in January.
Approvals spanned the full development spectrum—from early safety (Phase 1) to late-stage confirmatory trials (Phase 3/3b)—with oncology again taking the lead, alongside a balanced mix of immunology/inflammation, metabolic–cardiovascular, and CNS/psychiatry programs.
February 2026 MFDS IND Highlights (Key Summary)
- Total approvals: 39 INDs
- Sponsor origin (Development type):
- Domestic: 8 (~21%)
- Global: 31 (~79%)
- Trial phase distribution:
- Phase 3: 16
- Phase 1: 8
- Phase 2: 5
- Mixed/combined phases (Phase 1/2, 1/2a, 2a, 2b, 2/3, 3a, 3b, etc.): 10
- Top therapeutic area:
- Oncology: 16 trials (~41%), the largest share
- Operational note: approvals clustered mid-month, with a noticeable peak on Feb 19 (9 approvals)
- Full dataset:
- The full February 2026 MFDS IND list is available for download on our website
Approval Trend by Development Type: Domestic vs. Global
In February 2026, the approval structure remained clearly Global-led. Of 39 total approvals, 31 (~79%) were classified as Global, reinforcing Korea’s role as a core execution country in multinational clinical development.
A key pattern is that Global INDs skewed toward later-stage trials: within the 31 Global approvals, Phase 3 accounted for 15, suggesting that multinational sponsors continue to position Korea as a strategic country for confirmatory-stage programs, not merely a “participating site country.”
Meanwhile, Domestic approvals (8) remained meaningful, with a strong tilt toward early clinical development—notably Phase 1 (5). This indicates local pharma/biotech are actively moving pipelines into the clinic and building foundational human data to support future partnering and global expansion.
Therapeutic Area Signals
Oncology dominated (~41%), covering diverse tumor types (solid and hematologic) and including advanced approaches such as immuno-oncology, targeted therapies, and combination strategies, often aligned with platform/basket-style execution needs.
Beyond oncology, the month showed a broad, balanced distribution:
- Immunology & Inflammation (7): lupus nephritis, Crohn’s disease, ulcerative colitis, Graves’ disease, psoriatic arthritis
- Metabolic & Cardiovascular (6): obesity–heart failure, type 2 diabetes, metabolic-associated liver disease (MASLD) outcome-focused programs
- CNS & Psychiatry (4): Alzheimer’s disease, major depressive disorder, alcohol use disorder
- Rare/Genetic (select cases): e.g., hereditary angioedema
Overall, Korea’s IND mix suggests capability beyond any single therapy area—supporting a portfolio-wide global trial footprint across modalities and designs.
Strategic Implications
- Global sponsors: Korea continues to be utilized as a late-stage (Phase 3/confirmatory) priority country
- Domestic developers: early-phase execution remains central for data generation → partnering/licensing readiness
- MFDS throughput: February maintained stable approval volume (39), with observable batching around specific dates (e.g., Feb 19)
- Operational strategy: rising complexity (combination trials, platform/basket logic, biomarker-driven cohorts) increases the importance of site capability, patient recruitment execution, and globally acceptable data quality
Conclusion
The February 2026 MFDS IND approvals reinforce a structural trend: Korea is strengthening its position as a late-stage global trial hub, while domestic innovators continue to expand early clinical pipelines to build global credibility.
Following January’s momentum, February’s profile suggests Korea’s strategic weight in 2026 global clinical planning is likely to increase further—both for confirmatory programs and for early-to-mid stage innovation scaling.
